Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified

Leukemia volume 27, pages 2382–2385 (2013)Cite this article

Subjects

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the largest category of aggressive lymphoma; it is regarded as a heterogeneous group of lymphomas in terms of surface marker expression, histology and clinical features.1 In this study, we assessed the expression profiles of CC chemokine receptor 4 (CCR4) in DLBCL, NOS cells.

We examined 80 previously untreated patients with DLBCL, NOS who were diagnosed and treated between 2002 and 2012. All patients were initially treated with an R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Diagnosis of DLBCL, NOS was based on the World Health Organization classification system.1 Patients were classified into the following four groups on the basis of the International Prognostic Index (IPI) classification: low risk (IPI score=0–1), low–intermediate risk (IPI score=2), high–intermediate risk (IPI score=3) and high risk (IPI score=4–5).2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Stein H, Chan JKC, Warnke RA, Gatter KC, Chan WC, Campo E et al. Diffuse large B-cell lymphoma, not otherwise specified. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pilevi SA, Stein H et al (eds). World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissue. IARC Press: Lyon, France, 2008; pp 233–237.

    Google Scholar 

  2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  3. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

    Article  CAS  Google Scholar 

  4. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815–821.

    Article  CAS  Google Scholar 

  5. Noh J, Choi WS, Noh G, Lee JH . Presence of Foxp3-expressing CD19(+)CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg). Immune Netw 2010; 10: 247–249.

    Article  Google Scholar 

  6. Noh G, Lee JH . Regulatory B cells and allergic diseases. Allergy Asthma Immunol Res 2011; 3: 168–177.

    Article  CAS  Google Scholar 

  7. Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494–5500.

    Article  CAS  Google Scholar 

  8. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625–3634.

    CAS  PubMed  Google Scholar 

  9. Ishida T, Ueda R . Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102: 44–50.

    Article  CAS  Google Scholar 

  10. Roncador G, Garcia JF, Garcia JF, Maestre L, Lucas E, Menarguez J et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005; 19: 2247–2253.

    Article  CAS  Google Scholar 

  11. Ishida T, Inagaki H, Kusumoto S, Inagaki A, Komatsu H, Iida S et al. CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case report. Int J Hematol 2005; 82: 148–151.

    Article  Google Scholar 

  12. Nakayama-Ichiyama S, Iwaki K, Yokote T, Tsuji M, Hirata Y, Hanafusa T . Expression of multiple cytokines and CCR4 in primary testicular diffuse large B-cell lymphoma, not otherwise specified, involving the skin. Br J Haematol 2012; 156: 420.

    Article  Google Scholar 

  13. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520–1531.

    Article  CAS  Google Scholar 

  14. Tobinai K, Takahashi T, Akinaga S . Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 2012; 7: 235–240.

    Article  Google Scholar 

  15. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837–842.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan

    S Nakayama, T Yokote, Y Hirata, K Iwaki, T Akioka, T Miyoshi, N Hiraoka, A Takayama, U Nishiwaki, Y Masuda & T Hanafusa

  2. Division of Mathematics, Osaka Medical College, Osaka, Japan

    Y Nishimura

  3. Division of Surgical Pathology, Osaka Medical College, Osaka, Japan

    M Tsuji

Authors
  1. S Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Yokote
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Iwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Akioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Hiraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Takayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U Nishiwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Hanafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Nakayama.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Disclaimer

The authors alone are responsible for the content and writing of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakayama, S., Yokote, T., Hirata, Y. et al. Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified. Leukemia 27, 2382–2385 (2013). https://doi.org/10.1038/leu.2013.128

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.128

Search

Advanced search

Quick links